Abstract
Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems. The drug-induced variant is even rarer. We describe two cases of this syndrome associated with the administration of the proteasome inhibitor bortezomib. The diagnostic criteria for drug-induced Sweet's syndrome as proposed by Walker and Cohen were fulfilled. Vasculitis and neutrophilic eccrine hidradenitis were excluded.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Boronic Acids / administration & dosage
-
Boronic Acids / adverse effects*
-
Bortezomib
-
Drug Administration Schedule
-
Erectile Dysfunction / chemically induced
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Male
-
Melphalan / administration & dosage
-
Methylprednisolone / therapeutic use
-
Multiple Myeloma / drug therapy
-
Pain / chemically induced
-
Peripheral Nervous System Diseases / chemically induced
-
Prednisolone / administration & dosage
-
Protease Inhibitors / administration & dosage
-
Protease Inhibitors / adverse effects*
-
Pyrazines / administration & dosage
-
Pyrazines / adverse effects*
-
Recurrence
-
Sleep Initiation and Maintenance Disorders / chemically induced
-
Sweet Syndrome / chemically induced*
-
Sweet Syndrome / diagnosis
-
Sweet Syndrome / drug therapy
-
Sweet Syndrome / pathology
-
Testicular Diseases / chemically induced
Substances
-
Boronic Acids
-
Immunosuppressive Agents
-
Protease Inhibitors
-
Pyrazines
-
Bortezomib
-
Prednisolone
-
Melphalan
-
Methylprednisolone